Atrial fibrillation(AF)is a major risk factor for stroke,exerting a significant influence on stroke progression and prognosis.Paroxysmal atrial fibrillation detected after stroke(PAFDAS)has attracted considerable attention due to its key role in stroke onset,progression,and recurrence.Studies show that extending the duration of electrocardiographic monitoring can increase detection rate of PAFDAS.Compared to patients with known atrial fibrillation before stroke,those with PAFDAS exhibit better clinical outcomes,including lower risks of bleeding and mortality.However,there still remains controversy regarding anticoagulant therapy for secondary prevention in PAFDAS patients.Current evidence indicates that with regard to clinical outcomes,anticoagulant drugs does not demonstrate significant superiority over antiplatelet drugs,while concurrently posing an elevated risk of bleeding complications.Consequently,further research is warranted to establish optimal preventive strategies.This review focuses on examining the diagnostic criteria,analyzing the advantages and limitations of each electrocardiographic monitoring session,discussing the clinical outcomes of PAFDAS,with the goal of enhancing clinical recognition of PAFDAS.

Atrial fibrillation(AF)is a major risk factor for stroke,exerting a significant influence on stroke progression and prognosis.Paroxysmal atrial fibrillation detected after stroke(PAFDAS)has attracted considerable attention due to its key role in stroke onset,progression,and recurrence.Studies show that extending the duration of electrocardiographic monitoring can increase detection rate of PAFDAS.Compared to patients with known atrial fibrillation before stroke,those with PAFDAS exhibit better clinical outcomes,including lower risks of bleeding and mortality.However,there still remains controversy regarding anticoagulant therapy for secondary prevention in PAFDAS patients.Current evidence indicates that with regard to clinical outcomes,anticoagulant drugs does not demonstrate significant superiority over antiplatelet drugs,while concurrently posing an elevated risk of bleeding complications.Consequently,further research is warranted to establish optimal preventive strategies.This review focuses on examining the diagnostic criteria,analyzing the advantages and limitations of each electrocardiographic monitoring session,discussing the clinical outcomes of PAFDAS,with the goal of enhancing clinical recognition of PAFDAS.

Objective To investigate the effect of hyperthermic intraperitoneal perfusion and cisplatinon apoptosis in human ovarian cancer cells.Methods Two human ovarian cancer cells (OVCAR-3,A2780) were divided into control group,cisplatin group,hyperthermia group and thermo-chemotherapy group;microscopy was used to observe the morphological changes of the four groups;AO/GV stain and flow cytometry(FCM) was used to analyze cell apoptosis;Apoptosis related genes caspase7,caspase8 and Bax in ovarian cancer cells were detected by fluorescence quantitative PCR.Results Inverted microscopy observeed that the ovarian cancer cells retracted and suspended partially in the cisplatin group and hyperthermia group,especially in the thermo-chemotherapy group.After AO/GV staining,the apoptotic cells were increased in the cisplatin group and hyperthermia group compared with the control group,and the thermo-chemotherapy group was more than cisplatin group and hyperthermia group.FCM results indicated that the proportion of cells apoptosis were higher in the cisplatin group and hyperthermiagroup,the thermo-chemotherapy group is the higher than the all other groups(P＜0.05).q-PCR results showed that in the thermo-treatment group the expression of pro-apoptotic genes,including caspase3,caspase6,caspase7,caspase8,caspase9,Bax,Bak and Bid,was significantly higher than other groups,apoptosis inhibitory gennes,such as Bcl-2,Bcl-xL,Mcl-1,c-FLIP,was significantly decreased than the others.Conclusions Cisplatin plus hyperthermia can promote the apoptosis in ovarian cancer cells.